Interim Report Q3 2024
EBITDA fixed herd prices (FHP) for Q3 2024 decreased to 10.042 mEUR (Q3 2023: 13.663 kEUR), corresponding to an EBITDA margin FHP of 29.1% (Q3 2023: 36.3%). The quarterly EBITDA in Q3 2024 decreased by 3.621 kEUR (compared to Q3 2023). Mainly driven by negative effect by prices being, feed prices EUR -0,3m and sales prices EUR -3,5m.
- DARZALEX® (daratumumab) subcutaneous formulation shows 51 percent reduction in risk of progression to active multiple myeloma for patients with high-risk smouldering multiple myeloma - December 8, 2024
- Slate360 Provides Valuable Insights on the Advantages of Working with a Skilled Healthcare Event Marketing Agency - December 8, 2024
- Global Aerospace’s SM4 Aviation Safety Program Provides Actionable Advice for Enhancing Safety in Your Flight Department - December 8, 2024